Xtant Medical Holdings (NYSEAM:XTNT) has had its one-year price target adjusted to $1.38 per share, representing a decline of 10.00% from the previous estimate of $1.53 on February 21, 2026. The current targets from analysts range from a low of $1.21 to a high of $1.58 per share, with the average price target indicating a potential increase of 157.67% from the last reported closing price of $0.53 per share.
Institutional ownership in Xtant Medical has seen a slight decrease, with 38 funds reporting positions, down by 2.56% from the previous quarter. The average portfolio weight for these funds is 0.01%, which has increased by 83.65%. Total shares owned by institutions rose by 0.86% over the last three months to 81.4 million shares, with Nantahala Capital Management holding the largest share at 48.85% (68.4 million shares).
